Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU
Status:
Completed
Trial end date:
2019-02-05
Target enrollment:
Participant gender:
Summary
The BMN 165 clinical development program has been designed to demonstrate the safety and
efficacy of BMN 165 in reducing blood Phe concentrations in adults with PKU.